$2.17
0.93% yesterday
Nasdaq, Jul 15, 10:00 pm CET
ISIN
US0547544033
Symbol
AYTU

Aytu BioScience Inc Stock price

$2.17
+0.19 9.60% 1M
+0.54 32.72% 6M
+0.47 27.65% YTD
-0.65 23.05% 1Y
-9.80 81.87% 3Y
-261.83 99.18% 5Y
-364,797.83 100.00% 10Y
+1.85 578.13% 20Y
Nasdaq, Closing price Tue, Jul 15 2025
+0.02 0.93%
ISIN
US0547544033
Symbol
AYTU

Key metrics

Basic
Market capitalization
$13.4m
Enterprise Value
$16.6m
Net debt
$3.3m
Cash
$18.2m
Shares outstanding
6.2m
Valuation (TTM | estimate)
P/E
11.4 | 3.2
P/S
0.2 | 0.2
EV/Sales
0.2 | 0.2
EV/FCF
negative
P/B
0.4
Financial Health
Equity Ratio
23.5%
Return on Equity
-57.2%
ROCE
0.7%
ROIC
0.3%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$69.2m | $72.3m
EBITDA
$4.4m | $14.2m
EBIT
$368.0k | $3.1m
Net Income
$1.6m | $4.2m
Free Cash Flow
$-5.7m
Growth (TTM | estimate)
Revenue
-26.2% | -10.8%
EBITDA
-37.1% | 510.2%
EBIT
-80.9% | 205.6%
Net Income
112.0% | 126.2%
Free Cash Flow
-165.5%
Margin (TTM | estimate)
Gross
68.6%
EBITDA
6.4% | 19.6%
EBIT
0.5%
Net
2.4% | 5.8%
Free Cash Flow
-8.3%
More
EPS
$0.2
FCF per Share
$-0.9
Short interest
8.8%
Employees
102
Rev per Employee
$790.0k
Show more

Is Aytu BioScience Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Aytu BioScience Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Aytu BioScience Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Aytu BioScience Inc forecast:

Buy
86%
Hold
14%

Financial data from Aytu BioScience Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
69 69
26% 26%
100%
- Direct Costs 22 22
33% 33%
31%
47 47
22% 22%
69%
- Selling and Administrative Expenses 41 41
22% 22%
59%
- Research and Development Expense 2.15 2.15
3% 3%
3%
4.43 4.43
37% 37%
6%
- Depreciation and Amortization 4.07 4.07
20% 20%
6%
EBIT (Operating Income) EBIT 0.37 0.37
81% 81%
1%
Net Profit 1.64 1.64
112% 112%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Aytu BioScience Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aytu BioScience Inc Stock News

Neutral
Accesswire
21 days ago
DENVER, CO / ACCESS Newswire / June 25, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced the appointment of Dr. Gerwin Westfield, PhD as Senior Vice President of Scientific Affairs, effective June 30, 2025...
Neutral
Accesswire
23 days ago
Term loan maturity extended by 12 months to June 2029 Principal balance on term loan expanded to $13.0 million from $11.1 million currently Expanded revolving line of credit facility by $1.5 million Expanded facilities allow for added working capital flexibility as commercial launch of EXXUA is anticipated to occur in the fourth calendar quarter of 2025 DENVER, CO / ACCESS Newswire / June 23, 2...
Neutral
Accesswire
about one month ago
Gross proceeds from offering total $16.6 million. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders.
More Aytu BioScience Inc News

Company Profile

Aytu BioScience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Head office United States
CEO Joshua Disbrow
Employees 102
Founded 2002
Website aytubio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today